Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04208997 · ClinicalTrials.gov registry record · Phase 3
Continuation of Antiarrhythmics Following Ventricular Tachycardia Catheter Ablation
A Phase 3 study, sponsored by Vanderbilt University Medical Center.
- Terminated
- Registry status
- Phase 3
- Development phase
- 5
- Enrollment target
NCT04208997 is a Phase 3 study that was terminated before completion, run by Vanderbilt University Medical Center. The registered enrollment target is 5 participants.
The verdict
NCT04208997, a Phase 3 study, was terminated before completion, sponsored by Vanderbilt University Medical Center.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 5 participants
- Enrollment target
Study Summary
The investigators aim to study if patients that undergo catheter ablation for ventricular tachycardia benefit from continuation of Vaughan-Williams class III antiarrhythmic drugs for 3 months after their ablation.
Interventions
- DRUG Antiarrhythmic drug
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2019-12-19 |
| Est. Completion | 2021-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04208997
The ClinicalTrials.gov registry entry for NCT04208997 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Antiarrhythmic drug is the first listed.
NCT04208997 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04208997 about?
NCT04208997 is a clinical study titled "Continuation of Antiarrhythmics Following Ventricular Tachycardia Catheter Ablation". The investigators aim to study if patients that undergo catheter ablation for ventricular tachycardia benefit from continuation of Vaughan-Williams class III antiarrhythmic drugs for 3 months after their ablation.
What is the current status of trial NCT04208997?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 5 participants. The study started on 2019-12-19. Estimated completion is 2021-06-30.
What interventions are being tested in trial NCT04208997?
The interventions under investigation include: Antiarrhythmic drug (DRUG).
Who is sponsoring clinical trial NCT04208997?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.